124 related articles for article (PubMed ID: 12766036)
1. Expression of the lipogenic enzyme fatty acid synthase (FAS) in retinoblastoma and its correlation with tumor aggressiveness.
Camassei FD; Cozza R; Acquaviva A; Jenkner A; Ravà L; Gareri R; Donfrancesco A; Bosman C; Vadalà P; Hadjistilianou T; Boldrini R
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2399-403. PubMed ID: 12766036
[TBL] [Abstract][Full Text] [Related]
2. Clinico-pathological correlations of fatty acid synthase expression in retinoblastoma: an Indian cohort study.
Vandhana S; Deepa PR; Jayanthi U; Biswas J; Krishnakumar S
Exp Mol Pathol; 2011 Feb; 90(1):29-37. PubMed ID: 21111730
[TBL] [Abstract][Full Text] [Related]
3. EpCAM expression in retinoblastoma: a novel molecular target for therapy.
Krishnakumar S; Mohan A; Mallikarjuna K; Venkatesan N; Biswas J; Shanmugam MP; Ren-Heidenreich L
Invest Ophthalmol Vis Sci; 2004 Dec; 45(12):4247-50. PubMed ID: 15557427
[TBL] [Abstract][Full Text] [Related]
4. Expression of Fas ligand in retinoblastoma.
Krishnakumar S; Kandalam M; Mohan A; Iyer A; Venkatesan N; Biswas J; Shanmugam MP
Cancer; 2004 Oct; 101(7):1672-6. PubMed ID: 15378505
[TBL] [Abstract][Full Text] [Related]
5. Cox-2 expression in retinoblastoma.
Karim MM; Hayashi Y; Inoue M; Imai Y; Ito H; Yamamoto M
Am J Ophthalmol; 2000 Mar; 129(3):398-401. PubMed ID: 10704568
[TBL] [Abstract][Full Text] [Related]
6. Histopathological features and P-glycoprotein expression in retinoblastoma.
Filho JP; Correa ZM; Odashiro AN; Coutinho AB; Martins MC; Erwenne CM; Burnier MN
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3478-83. PubMed ID: 16186322
[TBL] [Abstract][Full Text] [Related]
7. The role of nitric oxide synthases and nitrotyrosine in retinoblastoma.
Adithi M; Nalini V; Krishnakumar S
Cancer; 2005 Apr; 103(8):1701-11. PubMed ID: 15754329
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of Fas expression in retinoblastoma.
Shanmugam MP; Lakshmi A; Biswas J; Krishnakumar S
Ocul Immunol Inflamm; 2003 Jun; 11(2):107-13. PubMed ID: 14533029
[TBL] [Abstract][Full Text] [Related]
9. Expression of C-kit in retinoblastoma: a potential therapeutic target.
Barry RJ; de Moura LR; Marshall JC; Fernandes BF; Orellana ME; Antecka E; Martins C; Burnier MN
Br J Ophthalmol; 2007 Nov; 91(11):1532-6. PubMed ID: 17591671
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress in retinoblastoma: correlations with clinicopathologic features and tumor invasiveness.
Deepa PR; Nalini V; Mallikarjuna K; Vandhana S; Krishnakumar S
Curr Eye Res; 2009 Dec; 34(12):1011-8. PubMed ID: 19958119
[TBL] [Abstract][Full Text] [Related]
11. Nm23 expression in retinoblastoma.
Krishnakumar S; Lakshmi A; Shanmugam MP; Vanitha K; Biswas J
Ocul Immunol Inflamm; 2004 Jun; 12(2):127-35. PubMed ID: 15512982
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of NADPH oxidase-4 as an indicator of reactive oxygen species stress in human retinoblastoma.
Singh L; Saini N; Pushker N; Sen S; Sharma A; Kashyap S
Int J Clin Oncol; 2016 Aug; 21(4):651-657. PubMed ID: 26857459
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of polo-like kinases in retinoblastoma: correlation with patient outcome, clinical and histopathological parameters.
Singh L; Pushker N; Sen S; Singh MK; Chauhan FA; Kashyap S
Clin Exp Ophthalmol; 2015 Aug; 43(6):550-7. PubMed ID: 25754767
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 expression in retinoblastoma: an immunohistochemical analysis.
Atchaneeyasakul LO; Uiprasertkul M; Trinavarat A
Curr Eye Res; 2010 Mar; 35(3):242-7. PubMed ID: 20373884
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of high-risk features of primary enucleation of patients with retinoblastoma in a tertiary center of a developing country in the era of intra-arterial chemotherapy.
Dikkaya F; Sarıcı AM; Erbek F; Celkan T; Mangan MS; Aydın Ö; Demirkesen C; Pazarlı H
Int Ophthalmol; 2018 Feb; 38(1):151-156. PubMed ID: 28058667
[TBL] [Abstract][Full Text] [Related]
16. Relationship between histopathological features of chemotherapy treated retinoblastoma and P-glycoprotein expression.
Souza Filho JP; Martins MC; Caissie AL; Torres VL; Fernandes LH; Erwenne CM; Burnier MN
Clin Exp Ophthalmol; 2005 Jun; 33(3):279-84. PubMed ID: 15932532
[TBL] [Abstract][Full Text] [Related]
17. Expression of high mobility group A2 protein in retinoblastoma and its association with clinicopathologic features.
Venkatesan N; Kandalam M; Pasricha G; Sumantran V; Manfioletti G; Ono SJ; Reddy MA; Krishnakumar S
J Pediatr Hematol Oncol; 2009 Mar; 31(3):209-14. PubMed ID: 19262251
[TBL] [Abstract][Full Text] [Related]
18. Expression of vascular endothelial growth factor in retinoblastoma.
Areán C; Orellana ME; Abourbih D; Abreu C; Pifano I; Burnier MN
Arch Ophthalmol; 2010 Feb; 128(2):223-9. PubMed ID: 20142546
[TBL] [Abstract][Full Text] [Related]
19. Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing.
Poulaki V; Mitsiades CS; McMullan C; Fanourakis G; Negri J; Goudopoulou A; Halikias IX; Voutsinas G; Tseleni-Balafouta S; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2005 Jan; 46(1):358-66. PubMed ID: 15623796
[TBL] [Abstract][Full Text] [Related]
20. Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation, invasion, and proliferation associated with let-7 down-regulation in retinoblastomas.
Mu G; Liu H; Zhou F; Xu X; Jiang H; Wang Y; Qu Y
Hum Pathol; 2010 Apr; 41(4):493-502. PubMed ID: 20004941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
